Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 1/2a Study of SPK002 as Pre-exposure Prophylaxis of COVID-19
2023-505279-62-00Phase 2Authorised
- Sponsor
- SpikImm
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of SPK002 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by SpikImm. Primary endpoints: Safety of SPK002, Pharmacokinetics of SPK002 and 1 more. Planned start Jul 2023; status: authorised.
02
Drugs
SPK002
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2023-505279-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505279-62-00.